AGBL4
Basic information
Region (hg38): 1:48532854-50023954
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the AGBL4 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 3 | |||||
missense | 25 | 28 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 2 | 2 | 4 | |||
non coding | 18 | 20 | ||||
Total | 0 | 0 | 43 | 4 | 4 |
Variants in AGBL4
This is a list of pathogenic ClinVar variants found in the AGBL4 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-48534220-C-T | not specified | Uncertain significance (Oct 29, 2021) | ||
1-48534223-C-T | not specified | Uncertain significance (Jul 25, 2023) | ||
1-48534246-G-A | not specified | Uncertain significance (May 04, 2023) | ||
1-48534250-G-T | not specified | Uncertain significance (Jan 10, 2023) | ||
1-48534255-C-T | not specified | Uncertain significance (Nov 21, 2023) | ||
1-48534893-C-T | not specified | Uncertain significance (Apr 09, 2024) | ||
1-48539679-C-T | AGBL4-related disorder | Benign (Mar 25, 2019) | ||
1-48539690-C-T | not specified | Uncertain significance (Oct 05, 2021) | ||
1-48587097-C-T | not specified | Uncertain significance (Jan 12, 2024) | ||
1-48587118-G-C | not specified | Uncertain significance (Feb 21, 2024) | ||
1-48587147-C-T | AGBL4-related disorder | Benign (Nov 25, 2019) | ||
1-48587148-G-A | not specified | Uncertain significance (Mar 14, 2023) | ||
1-48590894-C-T | not specified | Uncertain significance (May 27, 2022) | ||
1-48590895-G-A | not specified | Uncertain significance (Oct 13, 2023) | ||
1-48590913-T-C | not specified | Uncertain significance (Dec 01, 2022) | ||
1-48590923-C-T | not specified | Uncertain significance (May 26, 2023) | ||
1-48634513-C-A | not specified | Uncertain significance (Nov 18, 2023) | ||
1-48653368-T-A | not specified | Uncertain significance (Feb 28, 2024) | ||
1-48653385-T-C | not specified | Uncertain significance (Feb 08, 2023) | ||
1-48653403-C-T | not specified | Uncertain significance (Oct 06, 2022) | ||
1-48653448-A-G | not specified | Uncertain significance (Feb 15, 2023) | ||
1-48653455-G-A | AGBL4-related disorder | Benign (Oct 28, 2019) | ||
1-48663180-C-T | AGBL4-related disorder | Likely benign (Jul 12, 2019) | ||
1-48663230-C-T | not specified | Uncertain significance (Mar 25, 2024) | ||
1-48663232-C-T | AGBL4-related disorder | Benign (Jan 02, 2020) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
AGBL4 | protein_coding | protein_coding | ENST00000371839 | 14 | 1491059 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000248 | 0.996 | 124612 | 0 | 30 | 124642 | 0.000120 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.32 | 208 | 269 | 0.774 | 0.0000148 | 3303 |
Missense in Polyphen | 86 | 119.94 | 0.71705 | 1389 | ||
Synonymous | 0.887 | 85 | 96.1 | 0.885 | 0.00000490 | 912 |
Loss of Function | 2.55 | 14 | 28.8 | 0.486 | 0.00000165 | 338 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000933 | 0.0000933 |
Ashkenazi Jewish | 0.0000996 | 0.0000994 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000230 | 0.000221 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.000165 | 0.000165 |
dbNSFP
Source:
- Function
- FUNCTION: Metallocarboxypeptidase that mediates deglutamylation of target proteins. Catalyzes the deglutamylation of polyglutamate side chains generated by post-translational polyglutamylation in proteins such as tubulins. Also removes polyglutamates from the carboxy-terminus of target proteins such as MYLK. Mediates deglutamylation of CGAS, regulating the antiviral activity of CGAS. Acts as a long-chain deglutamylase and specifically shortens long polyglutamate chains, while it is not able to remove the branching point glutamate, a process catalyzed by AGBL5/CCP5. {ECO:0000250|UniProtKB:Q09LZ8}.;
- Pathway
- Post-translational protein modification;Metabolism of proteins;Carboxyterminal post-translational modifications of tubulin
(Consensus)
Recessive Scores
- pRec
- 0.104
Intolerance Scores
- loftool
- 0.503
- rvis_EVS
- 0.62
- rvis_percentile_EVS
- 83.25
Haploinsufficiency Scores
- pHI
- 0.299
- hipred
- N
- hipred_score
- 0.250
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.0654
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Agbl4
- Phenotype
- immune system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; cellular phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- proteolysis;protein deglutamylation;C-terminal protein deglutamylation;protein side chain deglutamylation;defense response to virus
- Cellular component
- Golgi apparatus;centriole;cytosol;ciliary basal body
- Molecular function
- metallocarboxypeptidase activity;zinc ion binding;tubulin binding